Ranbaxy Laboratories Ltd. faces a possibility of a permanent injunction in US, plunges almost 7% on BSE

Subscribe to GoodReturns

Ranbaxy Lab Ltd plunges almost 7% on BSE
Selling pressure saw the shares of Ranbaxy Laboratories witnessing dip of almost 7 per cent in the early trade on the Bombay Stock Exchange.

Ranbaxy Laboratories on Thursday had filed a consent decree with a U.S. court as part of its settlement with the U.S. authorities regarding a ban on certain manufacturing plants operated by the company in India and US.

The shares of the company were trading at 454.85 down 4.18 per cent at 10:00 hours

In a similar fashion, shares of the company were trading at Rs 454.65, down 4.18 per cent on the National Stock Exchange.

Meanwhile, the broader benchmark Sensex was quoting at 17,171.34, up 94.16 points at 10:00 hours

Read more about: ranbaxy, bse
Please Wait while comments are loading...
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'

Thousands of Goodreturn readers receive our evening newsletter.
Have you subscribed?